A previous study by Valachis et al (30) compared the efficacy and safety of the addition of lapatinib with the addition of trastuzumab, or a combination of the two, to neoadjuvant chemotherapy in HER2-positive breast cancer. The gene discussed is ERBB2; the disease is breast cancer.